Clinical and disease characteristics of study cohort
| . | IDH1mut . | IDH2mut . | IDH1/2mut∗ . | IDHWT . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | ||
| 123 | 165 | 286 | 2855 | ||||||
| Study cohort | |||||||||
| CCG/COG | 31 | 25.2% | 44 | 26.7% | 74 | 25.9% | 1798 | 63.0% | |
| Beat AML | 24 | 19.5% | 32 | 19.4% | 56 | 19.6% | 277 | 9.7% | |
| ECOG | 24 | 19.5% | 34 | 20.6% | 58 | 20.3% | 339 | 11.9% | |
| SWOG | 25 | 20.3% | 35 | 21.2% | 60 | 21.0% | 299 | 10.5% | |
| TCGA | 19 | 15.4% | 20 | 12.1% | 38 | 13.3% | 142 | 5.0% | |
| Age category (y) | |||||||||
| Pediatric (0-17) | 25 | 20.3% | 35 | 21.2% | 60 | 21.0% | 1684 | 59.1% | |
| AYA (18-39) | 25 | 20.3% | 25 | 15.2% | 49 | 17.1% | 395 | 13.9% | |
| Intermediate-age (40-59) | 48 | 39.0% | 65 | 39.4% | 113 | 39.5% | 527 | 18.5% | |
| Older (≥60) | 25 | 20.3% | 40 | 24.2% | 64 | 22.4% | 245 | 8.6% | |
| P value: IDHmut vs IDHWT | |||||||||
| Age: median (range) | 46.4 (4.3-87) | 51.4 (4.2-83) | 50.7 (4.2-87) | 15.6 (0.01-88) | <.001 | ||||
| IDH1mut | IDH2mut | IDH1/2mut∗ | IDHWT | ||||||
| n | % | n | % | n | % | n | % | ||
| Sex | |||||||||
| Male | 60 | 48.8% | 89 | 53.9% | 147 | 51.4% | 1503 | 52.7% | .683 |
| Female | 63 | 51.2% | 76 | 46.1% | 139 | 48.6% | 1351 | 47.3% | |
| WBC (×103/μL) | |||||||||
| Median (range), n = 3092 | 22.8 (0.6-201.1) | 14.3 (0.8-191.8) | 19.1 (0.6-201.1) | 21.9 (0.2-918.5) | .003 | ||||
| Peripheral blast, % | |||||||||
| Median (range), n = 2961 | 63 (0-98) | 45 (0-97) | 55 (0-98) | 38 (0-100) | .002 | ||||
| Bone marrow blast, % | |||||||||
| Median (range), n = 2582 | 79 (0-99) | 74 (11-100) | 76 (0-100) | 68 (0-100) | <.001 | ||||
| Platelet count (×103/μL) | |||||||||
| Median (range), n = 1799 | 65 (9-650) | 57.5 (8-9300) | 62 (8-9300) | 48 (0.7-7900) | <.001 | ||||
| Cytomolecular risk group | |||||||||
| Favorable | 30 | 26.3% | 42 | 29.2% | 72 | 28.1% | 916 | 33.7% | .071 |
| Intermediate | 61 | 53.5% | 73 | 50.7% | 132 | 51.6% | 968 | 35.6% | <.001 |
| Adverse | 23 | 20.2% | 29 | 20.1% | 52 | 20.3% | 836 | 30.7% | .001 |
| Unknown | 9 | 21 | 30 | 135 | |||||
| . | IDH1mut . | IDH2mut . | IDH1/2mut∗ . | IDHWT . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | ||
| 123 | 165 | 286 | 2855 | ||||||
| Study cohort | |||||||||
| CCG/COG | 31 | 25.2% | 44 | 26.7% | 74 | 25.9% | 1798 | 63.0% | |
| Beat AML | 24 | 19.5% | 32 | 19.4% | 56 | 19.6% | 277 | 9.7% | |
| ECOG | 24 | 19.5% | 34 | 20.6% | 58 | 20.3% | 339 | 11.9% | |
| SWOG | 25 | 20.3% | 35 | 21.2% | 60 | 21.0% | 299 | 10.5% | |
| TCGA | 19 | 15.4% | 20 | 12.1% | 38 | 13.3% | 142 | 5.0% | |
| Age category (y) | |||||||||
| Pediatric (0-17) | 25 | 20.3% | 35 | 21.2% | 60 | 21.0% | 1684 | 59.1% | |
| AYA (18-39) | 25 | 20.3% | 25 | 15.2% | 49 | 17.1% | 395 | 13.9% | |
| Intermediate-age (40-59) | 48 | 39.0% | 65 | 39.4% | 113 | 39.5% | 527 | 18.5% | |
| Older (≥60) | 25 | 20.3% | 40 | 24.2% | 64 | 22.4% | 245 | 8.6% | |
| P value: IDHmut vs IDHWT | |||||||||
| Age: median (range) | 46.4 (4.3-87) | 51.4 (4.2-83) | 50.7 (4.2-87) | 15.6 (0.01-88) | <.001 | ||||
| IDH1mut | IDH2mut | IDH1/2mut∗ | IDHWT | ||||||
| n | % | n | % | n | % | n | % | ||
| Sex | |||||||||
| Male | 60 | 48.8% | 89 | 53.9% | 147 | 51.4% | 1503 | 52.7% | .683 |
| Female | 63 | 51.2% | 76 | 46.1% | 139 | 48.6% | 1351 | 47.3% | |
| WBC (×103/μL) | |||||||||
| Median (range), n = 3092 | 22.8 (0.6-201.1) | 14.3 (0.8-191.8) | 19.1 (0.6-201.1) | 21.9 (0.2-918.5) | .003 | ||||
| Peripheral blast, % | |||||||||
| Median (range), n = 2961 | 63 (0-98) | 45 (0-97) | 55 (0-98) | 38 (0-100) | .002 | ||||
| Bone marrow blast, % | |||||||||
| Median (range), n = 2582 | 79 (0-99) | 74 (11-100) | 76 (0-100) | 68 (0-100) | <.001 | ||||
| Platelet count (×103/μL) | |||||||||
| Median (range), n = 1799 | 65 (9-650) | 57.5 (8-9300) | 62 (8-9300) | 48 (0.7-7900) | <.001 | ||||
| Cytomolecular risk group | |||||||||
| Favorable | 30 | 26.3% | 42 | 29.2% | 72 | 28.1% | 916 | 33.7% | .071 |
| Intermediate | 61 | 53.5% | 73 | 50.7% | 132 | 51.6% | 968 | 35.6% | <.001 |
| Adverse | 23 | 20.2% | 29 | 20.1% | 52 | 20.3% | 836 | 30.7% | .001 |
| Unknown | 9 | 21 | 30 | 135 | |||||
Bolded values are statisically significant.